Our life-saving therapies are used for the prevention of blood-related disease in newborns, in cardiac surgery, organ transplantation and in the treatment of shock and burns. CSL Behring, providing biotherapies for life for more than a century.
|1901||Emil von Behring wins first Nobel Prize in Medicine|
German doctor Emil von Behring wins the first Nobel Prize in Physiology and Medicine for his work on serum therapies. Von Behring’s pioneering work results in the modern methods of immunization that have largely eradicated diphtheria worldwide.
|1904||Emil von Behring creates Behringwerke|
Emil von Behring creates Behringwerke to produce sera and vaccines to combat infectious diseases.
Behringwerke expands to produce a gas gangrene antiserum and a cholera vaccine.
|1940||WWII: Largest supplier of albumin for U.S. military|
Armour becomes the largest supplier of human albumin for the U.S. military during World War II.
|1946||Europe’s first human plasma fractionation|
Behringwerke is the first company in Europe to begin fractionating plasma proteins from human plasma on an industrial scale.
The Zentrallaboratorium Blutspendedienst (ZLB) is established in Bern as a department of the Swiss Red Cross and holds its first blood donor sessions in Switzerland.
||ZLB mandate to supply blood products
ZLB receives a mandate from the Swiss government to supply blood products through the Swiss Red Cross Blood Transfusion Service.
|1954||First pasteurized plasma protein solution
ZLB produces the first pasteurized plasma protein solution.
|1955||Behringwerke researchers discover Alpha-1|
Alpha1-antitrypsin, a proteinase inhibitor, is discovered, purified and characterized for the first time by researchers of Behringwerke.
||New fractionation process published
Kistler and Nitschmann establish a plasma fractionation method that provides significantly better yields of the valuable proteins isolated from human plasma.
|1970||Japan’s first IVIg|
Launch of Gamma-Venin®, the first IVIg product in Japan.
||Launch of first purified IVIg
ZLB and Sandoz AG, Switzerland, launch Sandoglobulin®, the world’s first purified immunoglobulin product for intravenous infusion.
|1981||World’s first pasteurized factor VIII therapy|
Haemate® human plasma coagulation factor VIII/von Willebrand factor complex is first marketed in Europe for the treatment of patients with hemophilia A. It is the first pasteurized factor VIII product in the world.
|1984||First IVIg approved in U.S.
ZLB's polyvalent immunoglobulin is the first IVIg product to be approved in the United States.
|1986||Humate-P® approved in U.S.|
FDA approves Humate-P® human coagulation factor VIII/von Willebrand factor complex for the prevention and control of hemorrhagic episodes in patients with hemophilia A.
|1988||Japan’s first fibrin sealant|
Launch of Beriplast® P, the first fibrin sealant in Japan.
Monoclate®-P, the second generation form of Monoclate Factor VIII using monoclonal antibody technology, adds pasteurization as an additional viral removal step.
|1993||Helixate® approved in U.S.|
The FDA approves Helixate® recombinant coagulation factor VIII for the treatment of hemophilia A.
||World’s first anti-D immunoglobulin launched
Rhophylac®, the world’s first anti-D immunoglobulin for the prevention of hemolytic disease of the newborn due to Rh factor incompatibility, is launched.
|1998||€50 million plant modernization
A major, 50 million euro capital project is completed to modernize production facilities in Marburg, Germany.
|1999||Marburg: State-of-the-art Ig facility|
A state-of-the-art production building for immunoglobulins is built in Marburg, Germany.
|2000||New formulation of recombinant Factor VIII|
Helixate® FS/ Helixate® NexGen recombinant coagulation factor VIII formulated with sucrose for the treatment of hemophilia A. Approved by FDA for use in U.S. and by EMEA for use in 15 countries.
||ZLB Bioplasma established
CSL acquires ZLB Blood Transfusion Service from the Swiss Red Cross to establish ZLB Bioplasma, headquartered in Bern.
|2000||Gettin’ in the Game|
The company launches Gettin’ in the Game, local workshops that promote the value of exercise among children with bleeding disorders.
||ZLB Plasma Services established
CSL acquires 47 plasma collection centers and laboratory facilities operated by Nabi Plasma Collection Centers (U.S.) and creates ZLB Plasma Services.
|2001||World’s largest plasma collection business|
Aventis Behring acquires 42 plasma centers from Serologicals, forming the world’s largest plasma collection business.
The company establishes a foundation for research and advancement of patient health—the only non-profit foundation dedicated exclusively to charitable, scientific and educational endeavors that benefit the bleeding disorders community.
|2002||Junior National Championships|
The company launches Junior National Championships in partnership with the National Hemophilia Foundation to promote the value of exercise for children with bleeding disorders.
|2003||Carimune® NF launched in U.S.
The company begins marketing Carimune® NF the first nanofiltered human normal immunoglobulin for intravenous (IV) administration in the United States.
|2003||Zemaira® approved in U.S.|
FDA approves Zemaira® human alpha1-proteinase inhibitor for individuals with alpha1-proteinase inhibitor deficiency and clinical evidence of emphysema.
|2003||Assurance Program launched|
The Assurance Program is launched to ensure that people who rely on our recombinant and plasma-derived therapies can continue to receive these vital treatments even if they experience a lapse in third-party, private health insurance.
||ZLB Behring established
CSL completes the acquisition of Aventis Behring, combining it with ZLB Bioplasma to create ZLB Behring.
|2004||EMEA approves Mononine®|
The EMEA approves Mononine® human coagulation factor IX concentrate for the treatment of hemophilia B patients undergoing surgery, exposed to trauma, or experiencing severe, spontaneous hemorrhage. The company becomes the first to market a factor IX product approved for this method of treating these indications.
|2004||Rhophylac® approved in U.S.|
ZLB’s Rhophylac® human anti-D immunoglobulin is approved by the FDA.
ZLB Behring introduces the Mix2Vial™ alternate transfer device, a new way to reconstitute products.
|2006||Groundbreaking: state-of-the-art Ig plant|
Construction begins on a new immunoglobulin manufacturing plant at ZLB Behring’s Bern, Switzerland, facility.
|2006||Vivaglobin® approved in U.K.|
Vivaglobin® licensed for use in the U.K. in adults and children who require antibody replacement due to primary immunodeficiency.
|2006||State-of-the-art plant licensed by FDA|
Highly automated facility in Kankakee, Illinois to allow for increased production of Zemaira®.
|2006||Vivaglobin® first SCIg in U.S.|
U.S. Food and Drug Administration (FDA) grants marketing approval for Vivaglobin® human normal immunoglobulin for subcutaneous administration. Vivaglobin is the first FDA-approved subcutaneous immunoglobulin (SCIg) treatment.
|2006||Humate-P® 50% volume reduction|
Humate-P® human coagulation factor VIII/von Willebrand factor complex is now available featuring a smaller diluent—50 percent less in all assay sizes, shortening infusion time and requiring less storage space.
||ZLB Behring acquires CytoGam®
CytoGam® is an IVIg enriched with antibodies against cytomegalovirus, the most common cause of life-threatening infection occurring in solid organ transplants.
||Two Ig formulations available in Canada
With the approvals of Sandoglobulin® NF Liquid IVIg and Vivaglobin® subcutaneous Ig, ZLB Behring becomes the only company to offer two formulations of immunoglobulin for people with primary immune deficiency in Canada.
||ZLB Behring adopts the name CSL Behring
As part of our global brand alignment, we adopt the name CSL Behring. Our name may change, but who we are remains the same.
|CSL Behring continues to build on this legacy of innovation and patient care.|